2018
Gadolinium Retention: A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates
McDonald R, Levine D, Weinreb J, Kanal E, Davenport M, Ellis J, Jacobs P, Lenkinski R, Maravilla K, Prince M, Rowley H, Tweedle M, Kressel H. Gadolinium Retention: A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates. Radiology 2018, 289: 517-534. PMID: 30204075, PMCID: PMC6209069, DOI: 10.1148/radiol.2018181151.Peer-Reviewed Original ResearchConceptsGadolinium retentionLong-term clinical manifestationsConstellation of symptomsGBCA exposureClinical manifestationsHuman tissuesSafety profileClinical diseaseInitial approvalClinical importanceGBCA administrationGreater riskBiologic activityVulnerable populationsStandardized studiesImaging modalitiesNational InstituteLinear GBCAsGBCAsSymptomsCurrent literatureDiseaseAdditional researchFuture research initiativesMedical information
1999
Three-dimensional Gadolinium-enhanced MR Venographic Evaluation of Patency of Central Veins in the Thorax: Initial Experience
Shinde T, Lee V, Rofsky N, Krinsky G, Weinreb J. Three-dimensional Gadolinium-enhanced MR Venographic Evaluation of Patency of Central Veins in the Thorax: Initial Experience. Radiology 1999, 213: 555-60. PMID: 10551241, DOI: 10.1148/radiology.213.2.r99nv27555.Peer-Reviewed Original ResearchConceptsVenographic findingsCentral veinMR venographyCatheter placementConventional venographyCentral venous catheter placementArteriovenous hemodialysis graftsHemodialysis catheter placementThoracic central veinsVenous access sitesMagnetic resonance venographyVenous access devicesVenous catheter placementMultiplanar reconstruction imagesVenographic evaluationFourth patientHemodialysis graftsRetrospective studyMedical recordsAccess siteIntravenous administrationThree-dimensional GadoliniumVenographyPatientsContrast material
1997
Peripheral vascular disease evaluated with reduced-dose gadolinium-enhanced MR angiography.
Rofsky N, Johnson G, Adelman M, Rosen R, Krinsky G, Weinreb J. Peripheral vascular disease evaluated with reduced-dose gadolinium-enhanced MR angiography. Radiology 1997, 205: 163-9. PMID: 9314979, DOI: 10.1148/radiology.205.1.9314979.Peer-Reviewed Original ResearchConceptsPeripheral vascular diseaseGadolinium-enhanced MR angiographyDigital subtraction angiographyVascular diseaseMR angiographyGadopentetate dimeglumineLower extremity peripheral vascular diseasePeripheral vascular areasExtent of diseaseMR angiography findingsGadolinium-enhanced magnetic resonance angiographyMagnetic resonance angiographyConventional digital subtraction angiographyStandard of referenceAngiography findingsMost patientsLess stenosisTreatment optionsLower extremitiesDSA findingsVascular areaAngiographyAnatomic segmentsAnatomic areasContrast materialGadolinium-enhanced body MR venography with subtraction technique.
Lebowitz J, Rofsky N, Krinsky G, Weinreb J. Gadolinium-enhanced body MR venography with subtraction technique. American Journal Of Roentgenology 1997, 169: 755-8. PMID: 9275892, DOI: 10.2214/ajr.169.3.9275892.Peer-Reviewed Original ResearchSuppression of venous signal in time-of-flight MR angiography of the lower extremities after administration of gadopentetate dimeglumine.
Rofsky N, Purdy D, Johnson G, DeCorato D, Earls J, Krinsky G, Weinreb J. Suppression of venous signal in time-of-flight MR angiography of the lower extremities after administration of gadopentetate dimeglumine. Radiology 1997, 202: 177-82. PMID: 8988209, DOI: 10.1148/radiology.202.1.8988209.Peer-Reviewed Original ResearchConceptsGadopentetate dimeglumineLower extremitiesMR angiographyPeripheral vascular diseaseVenous signalDistal lower extremityMR angiogramsGadopentetate dimeglumine administrationStudent's t-testFlight MR angiographyAdult patientsAngiography timeVascular diseaseFlight MR angiogramsGradient echo sequenceAdministrationDimegluminePatientsAngiographyT-testAngiogramsExtremitiesMuscle tissueVenous suppressionImaging sectionsThoracic aorta: comparison of gadolinium-enhanced three-dimensional MR angiography with conventional MR imaging.
Krinsky G, Rofsky N, DeCorato D, Weinreb J, Earls J, Flyer M, Galloway A, Colvin S. Thoracic aorta: comparison of gadolinium-enhanced three-dimensional MR angiography with conventional MR imaging. Radiology 1997, 202: 183-93. PMID: 8988210, DOI: 10.1148/radiology.202.1.8988210.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAorta, ThoracicAortic Aneurysm, ThoracicAortic CoarctationAortic DiseasesAortic DissectionContrast MediaDrug CombinationsFemaleGadoliniumGadolinium DTPAHumansImage Processing, Computer-AssistedInfant, NewbornMagnetic Resonance AngiographyMagnetic Resonance ImagingMaleMeglumineMiddle AgedOrganometallic CompoundsPentetic AcidRetrospective StudiesConceptsThoracic aortic diseaseThree-dimensional MR angiographyConventional MR imagingMR angiographyIntramural hematomaAortic dissectionAortic diseaseVessel diseaseMR imagingFindings of surgeryChronic aortic dissectionThoracic MR imagingComparison of gadoliniumMagnetic resonance angiographyThree-dimensional magnetic resonance angiographyDiagnosis of aneurysmConsecutive patientsAngiographyResonance angiographyMR examinationsGadopentetate dimeglumineReader B.DiseaseGradient echo sequenceConventional MRHepatic arterial-phase dynamic gadolinium-enhanced MR imaging: optimization with a test examination and a power injector.
Earls J, Rofsky N, DeCorato D, Krinsky G, Weinreb J. Hepatic arterial-phase dynamic gadolinium-enhanced MR imaging: optimization with a test examination and a power injector. Radiology 1997, 202: 268-73. PMID: 8988222, DOI: 10.1148/radiology.202.1.8988222.Peer-Reviewed Original Research
1996
Image subtraction in gadolinium-enhanced MR imaging.
Lee V, Flyer M, Weinreb J, Krinsky G, Rofsky N. Image subtraction in gadolinium-enhanced MR imaging. American Journal Of Roentgenology 1996, 167: 1427-32. PMID: 8956572, DOI: 10.2214/ajr.167.6.8956572.Peer-Reviewed Original ResearchGadolinium-enhanced three-dimensional MR angiography of the thoracoabdominal aorta
Krinsky G, Weinreb J. Gadolinium-enhanced three-dimensional MR angiography of the thoracoabdominal aorta. Seminars In Ultrasound CT And MRI 1996, 17: 280-303. PMID: 8858769, DOI: 10.1016/s0887-2171(96)90017-7.Peer-Reviewed Original ResearchConceptsTurbulent flowIntravoxel phase dispersionNoise ratioSaturation effectsStagnant flowGood spatial resolutionPhase dispersionEase of implementationSpatial resolutionSignal lossFlight imagingFlowImproved hardwarePhased-array coilTOF techniqueHigh signalStrong gradientsImage degradationSignal enhancementExcellent image qualityUltrashort timeInplaneImage qualityTwo-dimensional timeHigh-resolution matrixNonspecificity of short inversion time inversion recovery (STIR) as a technique of fat suppression: pitfalls in image interpretation.
Krinsky G, Rofsky N, Weinreb J. Nonspecificity of short inversion time inversion recovery (STIR) as a technique of fat suppression: pitfalls in image interpretation. American Journal Of Roentgenology 1996, 166: 523-6. PMID: 8623620, DOI: 10.2214/ajr.166.3.8623620.Peer-Reviewed Original Research
1995
Gadoteridol-enhanced MR imaging of malignant hepatic tumors: effects of triple versus standard doses on lesion-liver contrast.
Petersein J, Saini S, Mitchell D, Davis P, Johnson C, Kuhlman J, Parisky Y, Runge V, Weinreb J, Bernardino M. Gadoteridol-enhanced MR imaging of malignant hepatic tumors: effects of triple versus standard doses on lesion-liver contrast. American Journal Of Roentgenology 1995, 165: 1157-61. PMID: 7572495, DOI: 10.2214/ajr.165.5.7572495.Peer-Reviewed Original ResearchConceptsLesion-liver CNRLesion-liver contrastStandard doseHepatic lesionsMR imagingMalignant hepatic tumorsMalignant liver lesionsMalignant hepatic massesAdministration of gadoteridolMalignant hepatic lesionsT1-weighted spin-echo imagingLiver MR imagingStandard dosesHepatic massHepatic tumorsTriple doseHigh doseMalignant lesionsLiver lesionsLesionsLiver SNRDoseTime pointsGradient-echo imagingLiver signalUreteral lymphoma: MRI demonstration
Lebowitz J, Rofsky N, Weinreb J, Friedmann P. Ureteral lymphoma: MRI demonstration. Abdominal Radiology 1995, 20: 173-175. PMID: 7787726, DOI: 10.1007/bf00201532.Peer-Reviewed Original Research
1994
Effect on fetal mouse development of exposure to MR imaging and gadopentetate dimeglumine
Rofsky N, Pizzarello D, Weinreb J, Ambrosino M, Rosenberg C. Effect on fetal mouse development of exposure to MR imaging and gadopentetate dimeglumine. Journal Of Magnetic Resonance Imaging 1994, 4: 805-807. PMID: 7865940, DOI: 10.1002/jmri.1880040611.Peer-Reviewed Original ResearchMeSH KeywordsAnalysis of VarianceAnimalsBody WeightContrast MediaDrug CombinationsEar, ExternalEmbryonic and Fetal DevelopmentExtremitiesEyeFemaleFetal DeathGadoliniumGadolinium DTPAGestational AgeHeadLitter SizeMagnetic Resonance ImagingMeglumineMiceOrganometallic CompoundsPentetic AcidPregnancySodium ChlorideConceptsDays of gestationIntraperitoneal injectionGadopentetate dimeglumineFetal weightEnd pointMR exposureMean fetal weightSaline injection groupMagnetic resonance exposurePregnant miceNormal salineFetal mouse developmentGroup 2Group 1Group 3Control groupGroup 4Group 5MR imagingAdverse effectsDimeglumineSignificant differencesGestationFetusesInjectionHepatic metastases and cavernous hemangiomas: distinction with standard- and triple-dose gadoteridol-enhanced MR imaging.
Mitchell D, Saini S, Weinreb J, De Lange E, Runge V, Kuhlman J, Parisky Y, Johnson C, Brown J, Schnall M. Hepatic metastases and cavernous hemangiomas: distinction with standard- and triple-dose gadoteridol-enhanced MR imaging. Radiology 1994, 193: 49-57. PMID: 8090921, DOI: 10.1148/radiology.193.1.8090921.Peer-Reviewed Original Research
1993
Use of the Magnetic Resonance Contrast Agent Gadodiamide in the Central Nervous System Results of a Multicenter Trial
SZE G, BRANT-ZAWADZKI M, McNAMARA M, HAUGHTON V, KUMAR A, MARAVILLA K, AISEN A, DREISBACH J, BRADLEY W, WEINREB J, DRAYER B, TSURUDA J, HESSELINK J, JOHNSON C, ZIMMERMAN R, WEINGAST G. Use of the Magnetic Resonance Contrast Agent Gadodiamide in the Central Nervous System Results of a Multicenter Trial. Investigative Radiology 1993, 28: s49-s55. PMID: 8486504, DOI: 10.1097/00004424-199303001-00006.Peer-Reviewed Original ResearchConceptsMagnetic resonance imagingPhase II/III clinical trialsVital signsCentral nervous system resultsSignificant adverse eventsNervous system resultsNonionic contrast agentsVisualization of lesionsPreinjection imagesAdverse eventsNeurologic statusMulticenter trialClinical statusMulticenter studyClinical trialsPatient's vital signsMRI scansGadodiamide injectionPatientsResonance imagingSafety parametersContrast enhancementInjectionTrialsSpineQuantitative analysis of gadopentetate dimeglumine excreted in breast milk
Rofsky N, Weinreb J, Litt A. Quantitative analysis of gadopentetate dimeglumine excreted in breast milk. Journal Of Magnetic Resonance Imaging 1993, 3: 131-132. PMID: 8428080, DOI: 10.1002/jmri.1880030122.Peer-Reviewed Original Research
1990
Pulmonary Artery Sarcoma
Weinreb J, Davis S, Berkmen Y, Isom W, Naidich D. Pulmonary Artery Sarcoma. Journal Of Computer Assisted Tomography 1990, 14: 647-649. PMID: 2370363, DOI: 10.1097/00004728-199007000-00025.Peer-Reviewed Original Research